Evidence map›Paper›PMID 32238066›Full record

ReviewJournal of cutaneous medicine and surgery

Incidence, Clinical Features, Management, and Prevention of Herpes Zoster in Patients Receiving Antitumor Necrosis Factor Therapy: A Clinical Review.

Byung-Soo Kim, Emanual Maverakis, Clarie Alexanian, Jenny Z Wang, Siba P Raychaudhuri

Abstract readReview
In one paragraph

Review in Journal of cutaneous medicine and surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Infections in psoriatic arthritis: association with treatment.Therapeutic advances in musculoskeletal disease · 2024
    Review
  6. Article
  7. Ramsay Hunt Syndrome in a Patient with Ulcerative Colitis Treated with Infliximab.European journal of case reports in internal medicine · 2021
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Byung-Soo Kim34996 Department of Dermatology, Pusan National University College of Medicine, Busan, Korea.ORCID https://orcid.org/0000-0003-0054-8570
Emanual Maverakis481070 Department of Dermatology, University of California School of Medicine, Davis, CA, USA.
Clarie Alexanian481070 Department of Dermatology, University of California School of Medicine, Davis, CA, USA.
Jenny Z Wang481070 Department of Dermatology, University of California School of Medicine, Davis, CA, USA.ORCID https://orcid.org/0000-0003-3924-5497
Siba P Raychaudhuri156053 VA Medical Center Sacramento, Division of Rheumatology & Immunology, Mather, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor necrosis factor (TNF) inhibitors have been used as an excellent therapeutic option in a variety of chronic inflammatory conditions. However, a recognized significant adverse effect of TNF inhibitor therapy is the increased risk of infections. The influence of TNF inhibitors on the course of coexisting or newly developed viral infections has not been extensively investigated. Therefore, we reviewed the recent publications to highlight the incidence, clinical features, management, and prevention of herpes zoster in patients who are receiving TNF inhibitors.

Indexed as

Antibodies, Monoclonal, HumanizedHerpes ZosterHumansIncidenceRisk FactorsTumor Necrosis Factor-alphaVirus ActivationAntibodies, Monoclonal, HumanizedTumor Necrosis Factor-alphaanti-TNF therapyherpes zosterTNF antagonistsTNF inhibitorsvaccinationvaricella zoster virus

Identifiers

PMID32238066
PMCPMC7238506

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.